logo
Lab-grown salmon is now FDA approved — here's why this one restaurant is putting it on the menu

Lab-grown salmon is now FDA approved — here's why this one restaurant is putting it on the menu

New York Post11-06-2025
Land ho! You've heard of fresh-caught salmon and even farm-raised — but what about lab-grown?
San Francisco cellular agriculture company Wildtype is the latest company to get FDA approval for its lab-grown salmon
Only three other companies have gotten the stamp of approval to sell cultivated salmon so far.
The company made waves in the food and culinary sectors after announcing that its hero product, saku salmon, got approved in 'a thorough pre-market safety consultation.'
Curious people can find the fish on the menu at Portland, Oregon, restaurant Kann — a James Beard award-winning Haitian spot by chef Gregory Gourdet.
For June, the cultured salmon will only grace the menu every Thursday night, but in July, it is slated to be a nightly offering.
'Our saku is sushi-grade and best served raw in dishes like sushi, crudo, and ceviche,' Wildtype explains on its website.
'We made it for world-class chefs who seek out the distinct flavor and freshness of raw seafood.'
And according to the FDA, they view lab-grown salmon 'as safe as comparable foods produced by other methods,' the FDA wrote in its public response letter.
The FDA's only gripe with Wildtype's cultivated salmon so far is that the company refers to it as 'cultured salmon cell material' — which is not 'our recommendation of that term as an appropriate common or usual name for declaring the substance in accordance with FDA's labeling requirements,' the agency said.
This interest in lab-grown salmon is due to both wild-caught and farm-raised versions containing levels of mercury. Wild-caught salmon is also susceptible to picking up chemicals in local waters.
So, how exactly is lab-grown salmon made?
The process can be broken down into three steps: source, grow and harvest. Living cells from Pacific salmon are taken from fish and then placed into cell cultivators that mimic the temperature, pH, and nutrients of a wild fish — allowing the cells to grow, as explained by Wildtype.
Once fully matured and harvested, the living 'salmon cells' are fused with plant-based ingredients that imitate the texture and appearance of true salmon.
Experts warn that typically, both wild-caught and farm-raised salmon contain traceable levels of mercury and are susceptible to picking up chemicals in local waters.
Oran Tantapakul – stock.adobe.com
By producing synthetic seafood, Wildtype says it aims to 'sustainably meet the food security challenges of this century' and minimize the damaging environmental implications of farming and fishing practices, while reducing 'exposure to common contaminants we'd rather avoid.'
According to the Washington State Department of Health, farmed salmon can sometimes be exposed to organic contaminants and pests like sea lice more often than wild-caught salmon, but rest assured: 'most of the salmon available for us to eat is farmed,' the agency says.
Synthetic salmon hasn't hit the grocery store shelves just yet but given cultural interest in plant-based, meatless, and lab-grown products — that day seems to be just around the corner.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asia-Pacific markets set to fall as traders await outcome of U.S.-China trade talks
Asia-Pacific markets set to fall as traders await outcome of U.S.-China trade talks

CNBC

time4 hours ago

  • CNBC

Asia-Pacific markets set to fall as traders await outcome of U.S.-China trade talks

Asia-Pacific markets were set to fall as investors awaited the outcome of the ongoing U.S.-China trade talks. Investors also await the result of the U.S. Federal Reserve meeting due Wednesday stateside, where it will make a decision on whether to cut interest rates. Good morning from Singapore. Asia markets are poised for a weaker open. Japan's benchmark Nikkei 225 was set to open lower, with the futures contract in Chicago at 40,920 while its counterpart in Osaka last traded at 40,820, against the index's last close of 40,998.27. Futures for Hong Kong's Hang Seng Index stood at 25,367, pointing to a weaker open compared with the HSI's last close of 25,562.13. Australia's S&P/ASX 200 was set to start the day lower with futures tied to the benchmark at 8,606, compared with its last close of 8,697.70. — Lee Ying Shan The S&P 500 closed near the flatline on Monday, with the latest trade deal between the U.S. and EU failing to spark a fresh rally. The broad market index inched up 0.02% to close at 6,389.77, while the Nasdaq Composite gained 0.33% to 21,178.58. The Dow Jones Industrial Average slipped 64.36 points, or 0.14%, to finish the session at 44,837.56. — Brian Evans

Sarepta will resume gene therapy shipments after FDA review of recent patient death
Sarepta will resume gene therapy shipments after FDA review of recent patient death

The Hill

time4 hours ago

  • The Hill

Sarepta will resume gene therapy shipments after FDA review of recent patient death

WASHINGTON (AP) — Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following a brief pause requested by regulators. The Food and Drug Administration said it recommended lifting the hold for young patients with Duchenne's muscular dystrophy who are still able to walk. Regulators had requested the pause after the deaths of two older teenagers who were taking the therapy. The FDA also said in a statement it determined that a recently reported death of an 8-year-old boy was unrelated to the therapy. Company shares surged more than 16% after the announcement to $13.86 in afterhours trading. The jump is the latest in a series of drastic stock movements triggered by changing fortunes for the company's best-selling product. Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects boys and young men, resulting in early death. It received accelerated approval in 2023 for a narrow range of young patients and was expanded last year for use in older patients, including those who can no longer walk. The FDA decision Monday 'significantly improves Elevidys' sales outlook in the near-term,' Jefferies analyst Andrew Tsai told investors, in a note after the announcement. 'The street will feel relieved about the situation, suggesting meaningful stock upside potential.' Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver injury, a known side effect of the treatment. The FDA then requested a pause in shipments of the drug after the death of a third patient taking a different Sarepta therapy. FDA officials have suggested the company will need to provide new study data on safety to resume Elevidys' use in older patients. 'The FDA will continue to work with the sponsor regarding non-ambulatory patients, which remains subject to a voluntary hold, following two deaths,' FDA said in its statement. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Sarepta will resume gene therapy shipments after FDA review of recent patient death
Sarepta will resume gene therapy shipments after FDA review of recent patient death

San Francisco Chronicle​

time4 hours ago

  • San Francisco Chronicle​

Sarepta will resume gene therapy shipments after FDA review of recent patient death

WASHINGTON (AP) — Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following a brief pause requested by regulators. The Food and Drug Administration said it recommended lifting the hold for young patients with Duchenne's muscular dystrophy who are still able to walk. Regulators had requested the pause after the deaths of two older teenagers who were taking the therapy. The FDA also said in a statement it determined that a recently reported death of an 8-year-old boy was unrelated to the therapy. Company shares surged more than 16% after the announcement to $13.86 in afterhours trading. The jump is the latest in a series of drastic stock movements triggered by changing fortunes for the company's best-selling product. Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects boys and young men, resulting in early death. It received accelerated approval in 2023 for a narrow range of young patients and was expanded last year for use in older patients, including those who can no longer walk. The FDA decision Monday 'significantly improves Elevidys' sales outlook in the near-term,' Jefferies analyst Andrew Tsai told investors, in a note after the announcement. 'The street will feel relieved about the situation, suggesting meaningful stock upside potential.' Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver injury, a known side effect of the treatment. The FDA then requested a pause in shipments of the drug after the death of a third patient taking a different Sarepta therapy. FDA officials have suggested the company will need to provide new study data on safety to resume Elevidys' use in older patients. 'The FDA will continue to work with the sponsor regarding non-ambulatory patients, which remains subject to a voluntary hold, following two deaths,' FDA said in its statement. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store